NEW YORK (GenomeWeb News) – InVivoScribe Technologies has received the CE IVD Mark for its LeukoStrat FLT3 Mutation Assay, the San Diego-based firm said today.

The PCR-based assay detects internal tandem duplications and point mutations in the FLT3 gene from whole blood or bone marrow in patients with acute myelogenous leukemia. According to privately held InVivoScribe, the mutation status of the FLT3 receptor gene is the most important prognostic indicator of disease outcome in cytogenically normal AML.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.

Sponsored by

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.

Sponsored by

In this webinar, Michael Quail of the R&D Sequencing team at the Wellcome Trust Sanger Institute will provide an expert perspective on library prep for next-generation sequencing.

Sponsored by

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.